Therma Bright Provides Update on FDA EUA Application Process For AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
Toronto, Ontario–(Newsfile Corp. – June 2, 2022) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of the smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive medical device technologies, is pleased to provide an update for the Company’s AcuVid™ COVID-19 Rapid Antigen Saliva Test and its U.S. Food and Drug Administration’s […]
Therma Bright to Submit Application to Health Canada for Approval of its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
Toronto, Ontario–(Newsfile Corp. – May 10, 2022) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), a progressive medical device technology company, is pleased to announce that it will submit an application to Health Canada for review of the Company’s AcuVid™ COVID-19 Rapid Antigen Saliva Test for detecting SARS CoV-2 virus in saliva. The […]
Therma Bright Receives Patent for a Device for Applying a Topical Treatment from U.S. Patent & Trademark Office (USPTO)
V.THRM | 2 hours ago Toronto, Ontario–(Newsfile Corp. – February 23, 2022) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that on February 4, 2022 the U.S. Patent and Trademark […]
Therma Bright Announces CAD$6 Million Private Placement with Institutional Investors
V.THRM | 1 hour ago Toronto, Ontario–(Newsfile Corp. – February 16, 2022) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has entered into a securities purchase agreement with […]
Therma Bright’s AcuVid(TM) U.S. Clinical Performance Study Successfully Exceeds U.S. Food & Drug Administration’s Emergency Use Authorization Requirements
V.THRM | 5 hours ago Toronto, Ontario–(Newsfile Corp. – February 15, 2022) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce its AcuVid™ COVID-19 Rapid Antigen Saliva Test for Point of […]
Therma Bright Provides Update on U.S. Clinical Performance Study
Toronto, Ontario–(Newsfile Corp. – January 20, 2022) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, announced today that its U.S. Clinical Performance Study is still underway. Once the clinical data has been completed […]
Therma Bright AcuVid(TM) COVID-19 Rapid Antigen Saliva Test’s Antibodies Successfully Detect the COVID-19 Omicron B.1.1.529 Variant
Toronto, Ontario–(Newsfile Corp. – December 16, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to confirm that antibodies incorporated in its AcuVid™ COVID-19 Rapid Antigen Saliva Test have been tested and can […]
Therma Bright to Begin AcuVid(TM) U.S. Clinical Performance Study with Receipt of IRB Conditional Approval
Toronto, Ontario–(Newsfile Corp. – November 12, 2021) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it will begin its U.S. clinical performance study with the receipt of Institutional […]
Therma Bright’s AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Successfully Detects the COVID-19 Delta Variant Strain
Toronto, Ontario–(Newsfile Corp. – July 8, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce the completion and validation that its AcuVid™ COVID-19 Rapid Antigen Saliva Test successfully detected the highly contagious, […]
Therma Bright Finalizes Agreement with Afero for Its Smart-Enabled AcuVid(TM) Saliva Test
Toronto, Ontario–(Newsfile Corp. – August 5, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of its ‘smart-enabled’ AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce it has completed the definitive partnership agreement with Afero, Inc. Afero’s next-generation Intelligent Edge “Smart” Platform will […]
